Design& In-Vitro Evaluation of Sustained Release Matrix Tablet of Repaglinide

Authors:

Gaurav Agarwal*, Shagun G, Surrender K and Shilpi A

DOI: 10.23880/beba-16000129

Volume 2, Issue 2

Abstract

The aim of present is to develop & evaluate Sustained release matrix tablet of Repaglinide. Repaglinide is an effective ant hyperglycemic. But owing to its shorter half life it needs frequent administration In present study, an attempt has been made to develop Sustained release matrix tablet of Repaglinide thereby reducing its frequency of administration & other dose related side effects. Various grades of HPMC (K4M & 15M), sodium alginate & Eudragit L 100 were used as hydrophilic matrix polymer. Croscarmellose was used as swelling agent. Total 12 formulations were prepared in trial batches. The formulations were evaluated for various pre compression & post compression parameters. All the formulations showed compliance with the pharmacopoeial standards. On the basis of evaluated parameters formulation F6 was considered to be the best one. Formulation F6 containing polymer sodium alginate showed 98.67% in-vitro drug release profile. The release data for formulation F6 was fitted to various mathematical models like zero order, first order, Krosmeyer Peppas & Higuchi model. It was observed that drug follows zero order kinetics & Higuchi model.

Keywords:

Repaglinide; Sustained Release Matrix; HPMC (K4M, K15M); Sodium alginate; Eudragit L 100; Croscarmellose; Wet Granulation

View PDF